- Home
- CTRM vs VYNE Comparison
CTRM vs VYNE Comparison
Compare CTRM & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRM | VYNE |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 20.0M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CTRM | VYNE |
|---|---|---|
| Price | $2.00 | $0.61 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.8K | ★ 293.5K |
| Earning Date | 12-03-2025 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.84 | $0.29 |
| 52 Week High | $2.67 | $1.98 |
Technical Indicators
Market Signals| Indicator | CTRM | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 33.29 | 49.71 |
| Support Level | $1.90 | $0.56 |
| Resistance Level | $2.20 | $0.60 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 0.00 | 35.56 |
Price Performance
Historical ComparisonAbout CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.